Tamoxifen (brand names: Valodex, Nolvadex, Istubal) is a non-steroidal compound acting primarily antiestrogen. From a medical point of view is used most often in the non-operative treatment of breast cancer (as adjuvant therapy). Their antiestrogenic due primarily to competition with endogenous estrogen for binding with the cellular receptor, thereby preventing or minimizing the possibility of binding of estrogens in the target tissue - largely nipples and uterus.
In sport is used as probably the most popular antiestrogen or a means of blocking action of estrogen in the body. Applies here only in men, because they have to worry about processing the aromatization of androgen excess in estrogens. These in turn cause in men effects feminizing such as:
- Gynecomastia or growth of adipose tissue around the breast
- fat, especially around the thighs, buttocks and abdomen
- the more 'plump' appearance as a result of the above-mentioned
- and also disrupt the hormonal balance... making us as a result of 'half-girl'
This is why men use tamoxifen for sport. One of the many myths that continue to circulate in the gyms, a statement allegedly weakened the action of anabolic steroids, mainly testosterone. Fortunately, there is no professional publications speaking about the fact that this is happening. Tamoxifen competes for the binding of the estrogen receptor and not the anabolic steroid ! In clinical studies have been carried out on a group of volunteers who were administered either testosterone (400 mg / week) as well as tamoxifen citrate (20 mg / day), the strength of the effect of testosterone and its metabolites ranged plus 3.4%, minus 3.6 %. Thus Test showed however that if affects tamoxyfen potency of testosterone, it has a positive impact on both the impact strength and the slight negative. And in fact, you can test other factors justify or say that, contrary to the fears of tamoxifen does not weaken, and certainly as much as suggested anabolic effects of testosterone.
- One film-coated tablet contains 10 mg of Nolvadex (tamoxifen citrate - 15.2 mg)
- One film-coated tablet Nolvadex D contains 20 mg of tamoxifen citrate - 30.4 mg
Excipients: lactose, corn starch, gelatin, sodium carboxymethyl cellulose polymer, magnesium stearate.
Coating: methylhydroxypropylcellulose, titanium dioxide, polyethylene glycol.
No data on the effects of Nolvadex on ability to drive and use machines in motion.
Treated patients may experience loss of menses. The drug may impair psychomotor performance, and therefore you should not drive or perform acts of precision in its application.
Do not drink alcohol during treatment because it increases the effects of alcohol.
The expected effect of treatment may change if Nolvadex is used in combination with other medicines. The intention to use of other drugs, including preparation should consult with a doctor.
The use of tamoxifen in premenopausal women some inhibition of menstruation occurs. During treatment with tamoxifen, an increase in the frequency of changes in the endometrium, such as hyperplasia, polyps, cancer. There was also an increased incidence of uterine sarcoma (mostly malignant mixed mesodermal tumors). The mechanism of these changes is not known. They are probably the result of the action of tamoxifen similar to estrogen. Particular caution should be exercised in patients who were previously treated with tamoxifen and during treatment occurred in these effects from the reproductive system especially vaginal bleeding, menstrual disorders, vaginal discharge, pain and (or) a feeling of heaviness in the lower abdomen. Caution should be exercised if, during the re-treatment with tamoxifen experience similar symptoms.
In clinical studies in patients treated with tamoxifen for breast cancer incidence of primary tumors other than breast or other cancer of the endometrium. Not been established causal link between the occurrence of these tumors and the administration of tamoxifen. The clinical significance of these findings is not clear.
The drug is generally well tolerated.
- Digestive Disorders-nausea, vomit
- Flushing, sweating
- Menstrual disorders
- The accumulation of water in the body
- Too high levels of calcium in the blood
- Reduction in the number of platelets
- Vaginal discharge and itching of the vagina
- Pain in the area of cancer
- The formation of blood clots
- Swelling of the ovaries, hair loss
- Disorders of liver function
- Elevated blood calcium levels in patients with metastatic cancer to the bone
- The weakening of eyesight
The side effects seen with tamoxifen result either from the pharmacological action of the drug, such as hot flashes, vaginal bleeding, vaginal discharge, itching of the vulva, transient symptoms of cancer, or the operation of general gastrointestinal disorders, headaches, poor attention and in very rare cases, fluid retention in the body, and alopecia. If side effects are severe, reduction of dose (dose not less than 20 mg per day) may reduce their severity. If, despite dose reduction severity of adverse reactions does not change, it may be necessary to discontinue the drug. In very rare cases, skin lesions, including isolated cases of multiform erythema, Stevens-Johnson syndrome, pemphigus. In rare cases, hypersensitivity reactions have occurred also in the form of angioedema. A small number of patients whose bone metastases were found during the initial period of treatment have elevated serum calcium.
During treatment with tamoxifen were reduced platelet count to 80 000 - 90 000 cells/mm3. In individual cases, the number was smaller. In patients treated with tamoxifen was also observed abnormal vision, including changes in the cornea, retinopathy, cataracts. Have been reported cases of uterine fibroids, endometriosis, and other changes in the endometrium, ie hyperplasia and polyps. For women aged premenopausal patients treated with Nolvadex in a few cases observed increase ovarian cysts. After application of Nolvadex has been observed leukopenia, sometimes she has performed with anemia and (or) thrombocytopenia. In very rare cases, neutropenia, sometimes severe. During tamoxifen treatment, cases of deep vein thrombosis and pulmonary embolism. Concomitant use of Nolvadex and cytotoxic drugs increases the risk of thromboembolic complications. In very rare cases, the occurrence of interstitial pneumonia. When treatment with Nolvadex, changes in liver enzymes. In rare cases other severe liver dysfunction, such as fatty liver, cholestasis and hepatitis. In rare cases, after application of Nolvadex, an increase in serum triglycerides, sometimes occurring simultaneously with pancreatitis. During treatment with Nolvadex an increased incidence of endometrial cancer and uterine sarcoma (mostly malignant mixed mesodermal tumors).